Instructions Gliaton soft capsules 400 mg blister No. 30
Composition
active ingredient: choline alfoscerate;
1 capsule contains choline alfoscerate 400 mg;
excipients: glycerin;
capsule shell composition: gelatin (160 bloom); sorbitol liquid, partially dehydrated; glycerin; iron oxide yellow (E 172); titanium dioxide (E 171); sodium ethyl parahydroxybenzoate;
sodium propyl parahydroxybenzoate (E 217); purified water.
Dosage form
Soft capsules.
Main physicochemical properties: soft gelatin capsules of oval shape, yellow-brown color. The contents of the capsules are a viscous solution.
Pharmacotherapeutic group
Agents affecting the nervous system. Parasympathomimetics. Choline alfoscerate.
ATX code N07A X02.
Pharmacological properties
Pharmacodynamics.
Gliaton® is a drug belonging to the group of central cholinomimetics with a predominant effect on the CNS. Choline alfoscerate as a choline carrier and a precursor of phosphatidylcholine has the potential to prevent and correct biochemical damage, which is of particular importance among the pathogenic factors of psychoorganic involutional syndrome, i.e. it can affect the reduced cholinergic tone and the altered phospholipid composition of nerve cell membranes. The drug contains 40.5% metabolically protected choline. Metabolic protection ensures the release of choline in the brain. Gliaton® has a positive effect on memory functions and cognitive abilities, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional brain pathology.
The mechanism of action is based on the fact that when choline enters the body, alfoscerate is broken down by enzymes into choline and glycerophosphate: choline takes part in the biosynthesis of acetylcholine - one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane. Thus, Gliaton® improves the transmission of nerve impulses in cholinergic neurons; has a positive effect on the plasticity of neuronal membranes and the function of receptors. Gliaton® improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.
Pharmacokinetics.
When Gliaton® is administered, on average, almost 88% of the administered dose is absorbed. The drug accumulates mainly in the brain (45% of the drug concentration in the blood), lungs, and liver.
Elimination of the drug occurs mainly through the lungs as carbon dioxide (CO2). Only 15% of the drug is excreted in the urine and bile.
Indication
Degenerative-involutional brain psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, i.e. primary and secondary disorders of mental activity in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; changes in the emotional and behavioral sphere: emotional instability, irritability, indifference to the environment; pseudomelancholia in the elderly.
Contraindication
Known hypersensitivity to the drug or its components.
Patients with psychotic syndrome, with severe psychomotor agitation.
Interaction with other medicinal products and other types of interactions
Clinically significant drug interactions with other drugs have not been established.
Application features
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Use during pregnancy or breastfeeding
The drug is contraindicated during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
The drug does not affect driving and working with other mechanisms.
Method of administration and doses
The drug should only be used by adults.
Take 1 capsule 2 or 3 times a day.
The duration of treatment is determined individually by the doctor.
Children
There is no experience with the use of Gliaton® in children.
Overdose
In case of overdose of Gliaton®, which may manifest as nausea, anxiety, agitation, insomnia, the dose of the drug should be reduced. Therapy is symptomatic.
Adverse reactions
As a rule, the drug is well tolerated even with long-term use.
During the first days or weeks of treatment, the following adverse reactions may occur: anxiety, agitation, insomnia. These symptoms are temporary and do not require discontinuation of treatment, but a temporary dose reduction is possible.
Hypersensitivity reactions including rash, itching, urticaria, angioedema, skin redness are possible. May cause allergic reactions (possibly delayed).
Expiration date
2 years.
Do not use the drug after the expiration date indicated on the package.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 capsules in a blister. 3 or 6 blisters in a pack.
Vacation category
According to the recipe.
Producer
PJSC "Farmak".
Location of the manufacturer and its business address
Ukraine, 04080, Kyiv, Frunze St., 74.
